Becton Dickinson and Co (BDX) Shares Sold by NEXT Financial Group Inc
NEXT Financial Group Inc reduced its position in shares of Becton Dickinson and Co (NYSE:BDX) by 10.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 713 shares of the medical instruments supplier’s stock after selling 85 shares during the period. NEXT Financial Group Inc’s holdings in Becton Dickinson and were worth $139,000 as of its most recent filing with the SEC.
A number of other large investors have also recently made changes to their positions in the stock. Crestwood Advisors Group LLC bought a new position in Becton Dickinson and during the first quarter worth $101,000. North Star Investment Management Corp. increased its position in shares of Becton Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 18 shares in the last quarter. Almanack Investment Partners LLC. acquired a new position in shares of Becton Dickinson and during the first quarter valued at approximately $105,000. Parkside Financial Bank & Trust increased its position in shares of Becton Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares in the last quarter. Finally, Financial Architects Inc increased its position in shares of Becton Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock valued at $124,000 after buying an additional 261 shares in the last quarter. 87.41% of the stock is currently owned by institutional investors and hedge funds.
Becton Dickinson and Co (NYSE BDX) traded down 0.39% during mid-day trading on Tuesday, reaching $198.27. The company had a trading volume of 184,382 shares. The stock has a 50-day moving average of $200.05 and a 200 day moving average of $189.42. The company has a market capitalization of $45.12 billion, a price-to-earnings ratio of 57.42 and a beta of 1.05. Becton Dickinson and Co has a 12-month low of $161.29 and a 12-month high of $206.63.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. Becton Dickinson and had a negative return on equity of 6.44% and a negative net margin of 4.38%. Becton Dickinson and’s revenue was down 5.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.35 EPS. On average, analysts expect that Becton Dickinson and Co will post $9.46 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.47%. Becton Dickinson and’s dividend payout ratio (DPR) is 83.43%.
WARNING: “Becton Dickinson and Co (BDX) Shares Sold by NEXT Financial Group Inc” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/becton-dickinson-and-co-bdx-shares-sold-by-next-financial-group-inc/1530011.html.
BDX has been the subject of several research analyst reports. Raymond James Financial, Inc. upgraded Becton Dickinson and from an “outperform” rating to a “strong-buy” rating and reduced their target price for the stock from $210.00 to $180.00 in a research note on Friday, June 30th. Zacks Investment Research downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, May 4th. Bank of America Corporation reiterated a “buy” rating and set a $225.00 target price (up from $200.00) on shares of Becton Dickinson and in a research note on Friday, July 21st. BidaskClub upgraded Becton Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Finally, Cowen and Company reiterated an “outperform” rating and set a $230.00 target price (up from $200.00) on shares of Becton Dickinson and in a research note on Monday, July 10th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $195.79.
In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the sale, the insider now directly owns 12,861 shares in the company, valued at approximately $2,538,890.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary M. Cohen sold 15,044 shares of the company’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $200.43, for a total value of $3,015,268.92. Following the completion of the sale, the insider now owns 95,270 shares of the company’s stock, valued at $19,094,966.10. The disclosure for this sale can be found here. Insiders sold a total of 48,605 shares of company stock valued at $9,718,986 over the last 90 days. 1.40% of the stock is currently owned by company insiders.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co and related companies with Analyst Ratings Network's FREE daily email newsletter.